<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Valneva Se — News on 6ix</title>
    <link>https://6ix.com/company/valneva-se</link>
    <description>Latest news and press releases for Valneva Se on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 26 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/valneva-se" rel="self" type="application/rss+xml" />
    <item>
      <title>Valneva to Participate in Multiple Events  at the 26th World Vaccine Congress in Washington DC</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-to-participate-in-multiple-events-at-the-26th-world-vaccine-congress-in-washington-dc</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-to-participate-in-multiple-events-at-the-26th-world-vaccine-congress-in-washington-dc</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming</description>
    </item>
    <item>
      <title>Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial</title>
      <link>https://6ix.com/company/valneva-se/news/pfizer-and-valneva-announce-lyme-disease-vaccine-candidate-demonstrates-strong-efficacy-in-phase-3-valor-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/pfizer-and-valneva-announce-lyme-disease-vaccine-candidate-demonstrates-strong-efficacy-in-phase-3-valor-trial</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The</description>
    </item>
    <item>
      <title>Valneva Reports Full Year 2025 Audited Consolidated Financial Results</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-reports-full-year-2025-audited-consolidated-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-reports-full-year-2025-audited-consolidated-financial-results</guid>
      <pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
      <description>Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with</description>
    </item>
    <item>
      <title>Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-to-report-full-year-2025-consolidated-financial-results-on-march-18-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-to-report-full-year-2025-consolidated-financial-results-on-march-18-2026-1</guid>
      <pubDate>Mon, 09 Mar 2026 16:45:00 GMT</pubDate>
      <description>Lyon (France), March 9, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The Company will host a live webcast beginning at 3 p.m. CET/10 a.m. EDT to discuss the financial results and provide a business update. The live webcast will be accessible on the Company’s website and made available as an archive after the event concludes. Please refer to this link: http</description>
    </item>
    <item>
      <title>Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026 </title>
      <link>https://6ix.com/company/valneva-se/news/valneva-to-report-full-year-2025-consolidated-financial-results-on-march-18-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-to-report-full-year-2025-consolidated-financial-results-on-march-18-2026</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>Lyon (France), March 9, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year</description>
    </item>
    <item>
      <title>VALNEVA  Declaration of shares and voting rights: February 28, 2026</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-declaration-of-shares-and-voting-rights-february-28-2026-138</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-declaration-of-shares-and-voting-rights-february-28-2026-138</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>VALNEVA Declaration of shares and voting rights February 28, 2026__________________________________________________________________________________________</description>
    </item>
    <item>
      <title>Valneva to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-to-participate-in-upcoming-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-to-participate-in-upcoming-investor-conferences</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present</description>
    </item>
    <item>
      <title>Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-reports-preliminary-unaudited-2025-revenue-and-cash-and-provides-2026-outlook</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-reports-preliminary-unaudited-2025-revenue-and-cash-and-provides-2026-outlook</guid>
      <pubDate>Thu, 19 Feb 2026 06:00:00 GMT</pubDate>
      <description>Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the yearChief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership Lyon (France), February 19, 2026 – Valneva SE (Nasdaq:</description>
    </item>
    <item>
      <title>Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-provides-recommendations-ixchiq-united-164500544</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-provides-recommendations-ixchiq-united-164500544</guid>
      <pubDate>Fri, 13 Feb 2026 16:45:00 GMT</pubDate>
      <description>Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s single‑dose chikungunya vaccine, IXCHIQ®, the United Kingdom’s (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine. The updated Prescribing Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age</description>
    </item>
    <item>
      <title>VALNEVA  Declaration of shares and voting rights: January 31, 2026</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-declaration-shares-voting-rights-170000262</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-declaration-shares-voting-rights-170000262</guid>
      <pubDate>Wed, 11 Feb 2026 17:00:00 GMT</pubDate>
      <description>VALNEVA Declaration of shares and voting rights January 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: correction as of February 11, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*D</description>
    </item>
    <item>
      <title>VALNEVA Declaration of shares and voting rights: January 31, 2026</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-declaration-shares-voting-rights-073000141</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-declaration-shares-voting-rights-073000141</guid>
      <pubDate>Fri, 06 Feb 2026 07:30:00 GMT</pubDate>
      <description>VALNEVA Declaration of shares and voting rights January 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: February 6, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the</description>
    </item>
    <item>
      <title>Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-and-instituto-butantan-announce-initiation-pilot-vaccination-campaign-0</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-and-instituto-butantan-announce-initiation-pilot-vaccination-campaign-0</guid>
      <pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
      <description>Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one</description>
    </item>
    <item>
      <title>Valneva Provides Update on Chikungunya Vaccine IXCHIQ®</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-provides-update-chikungunya-vaccine-ixchiqr-2026-01-19-0</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-provides-update-chikungunya-vaccine-ixchiqr-2026-01-19-0</guid>
      <pubDate>Mon, 19 Jan 2026 05:00:00 GMT</pubDate>
      <description>Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial</description>
    </item>
    <item>
      <title>Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-meet-investors-during-jp-morgan-healthcare-conference-2026-01-09-0</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-meet-investors-during-jp-morgan-healthcare-conference-2026-01-09-0</guid>
      <pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
      <description>Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its</description>
    </item>
    <item>
      <title>Valneva SE - Declaration of voting rights - December 2025</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-se-declaration-voting-rights-december-2025-2026-01-08</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-se-declaration-voting-rights-december-2025-2026-01-08</guid>
      <pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
      <description>VALNEVA Declaration of shares and voting rights December 31, 2025__________________________________________________________________________________________</description>
    </item>
    <item>
      <title>Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-and-serum-institute-india-announce-discontinuation-chikungunya-vaccine-0</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-and-serum-institute-india-announce-discontinuation-chikungunya-vaccine-0</guid>
      <pubDate>Wed, 31 Dec 2025 05:00:00 GMT</pubDate>
      <description>Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India</description>
    </item>
    <item>
      <title>Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-reports-positive-final-phase-2-antibody-persistence-and-safety-results-0</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-reports-positive-final-phase-2-antibody-persistence-and-safety-results-0</guid>
      <pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
      <description>IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high</description>
    </item>
    <item>
      <title>VALNEVA Declaration of shares and voting rights: November 30, 2025</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-declaration-shares-and-voting-rights-november-30-2025-2025-12-05</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-declaration-shares-and-voting-rights-november-30-2025-2025-12-05</guid>
      <pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
      <description>VALNEVA Declaration of shares and voting rights November 30, 2025__________________________________________________________________________________________</description>
    </item>
    <item>
      <title>Valneva to Further Consolidate its Operations in France</title>
      <link>https://6ix.com/company/valneva-se/news/valneva-further-consolidate-operations-france-163000570</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-further-consolidate-operations-france-163000570</guid>
      <pubDate>Wed, 26 Nov 2025 16:30:00 GMT</pubDate>
      <description>French operations to be concentrated at its Lyon site Final consolidation of R&amp;D in Vienna Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France as part of the Company’s ongoing efforts to increase operational effectiveness and position Valneva for long-term success. The Company plans to concentrate its French operations at its Lyon location, closing the site in Nantes,</description>
    </item>
    <item>
      <title>Valneva to Further Consolidate its Operations in France </title>
      <link>https://6ix.com/company/valneva-se/news/valneva-further-consolidate-its-operations-france-2025-11-26-0</link>
      <guid isPermaLink="true">https://6ix.com/company/valneva-se/news/valneva-further-consolidate-its-operations-france-2025-11-26-0</guid>
      <pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
      <description>French operations to be concentrated at its Lyon site Final consolidation of R&amp;D in Vienna Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq:</description>
    </item>
  </channel>
</rss>